The Board of Directors of the Company at its meeting held today May 27 2023 has inter alia considered andapproved the standalone and consolidated Audited Financial Results of the Company for the fourth quarter and yearended March 31 2023 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements)Regulations 2015. We enclose herewith the said Audited Financial Results of the Company along with the AuditReports issued by the Statutory Auditors of the Company.Pursuant to Regulation 33(3)(d) of SEBI Listing Regulations we hereby confirm and declare that the Statutory Auditorsof the Company M/s. Deloitte Haskins & Sells Chartered Accountants have issued the audit reports on Standaloneand Consolidated Financial Results of the Company for the fourth quarter and year ended March 31 2023 withunmodified opinion.
Aurobindo Pharma: Board Meeting Outcome for Outcome Of Board Meeting
May 27, 2023
Download PDF
Aurobindo Pharma
Informed fund ideas, better judgment. Every month. Mutual Fund Insight, every month since October 2002.
Take charge. Know more. Keep more. Mutual Fund Insight helps you do all three — every month